SYNIMMUNE GMBH
SYNIMMUNE GmbH is a biotechnology company dedicated to the development of innovative and effective mono- and bispecific anti-tumor antibodies for the treatment of patients suffering from life-threatening diseases, with a focus on orphan hematopoietic malignancies. SYNIMMUNE’s lead product candidate is the antibody FLYSYN, which is currently in a first-in-human phase I clinical study in acute myeloid leukemia (AML). SYNIMMUNE GmbH is a spin-off of the Department of Immunology of the University of Tuebingen. The Company is financed by grants from the German Ministry of Education and Research (BMBF) within its GO-Bio program as well as investments by the German KfW and private equity.
SYNIMMUNE GMBH
Social Links:
Industry:
Biotechnology Clinical Trials Education
Founded:
2010-07-07
Address:
Tübingen, Baden-Wurttemberg, Germany
Country:
Germany
Website Url:
http://www.synimmune.de
Status:
Active
Contact:
+49-7071-7708381
Email Addresses:
[email protected]
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro SPF Google Analytics LetsEncrypt SSL By Default Google Universal Analytics Apache AJAX Libraries API
Similar Organizations
Geneius
Geneius is a Biotechnology company.
Genosco
Genosco is a biotechnology company.
PamGene
PamGene is an European biotechnology company.
Themis Bioscience
Themis Bioscience is a start-up biotechnology company.
Current Employees Featured
Founder
More informations about "Synimmune GmbH"
Synimmune GmbH - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number +49-7071-7708381 SYNIMMUNE GmbH is a biotechnology company dedicated to the development of innovative and effective mono- and bispecific anti-tumor antibodies for the treatment of patients suffering from life-threatening …See details»
Synimmune Company Profile 2024: Valuation, Investors
Synimmune General Information Description. Operator of a biotechnology company intended to facilitate the treatment of life-threatening diseases. The company is dedicated to the …See details»
SYNIMMUNE (SYNIMMUNE GmbH) - Startbase
Hauptquartier: Tübingen, DE; Official Website: synimmune.de; On Social Media: Juristische Person: SYNIMMUNE GmbH Bundesland: Baden-Württemberg Übersicht Unternehmen …See details»
Veraxa
HEIDELBERG, Germany, January 29, 2024 --VERAXA Biotech GmbH, an emerging leader in designing novel cancer immunotherapies, today provided an update on its pipeline development strategy in light of the recent acquisition of …See details»
SYNIMMUNE GmbH, Tübingen - North Data
SYNIMMUNE GmbH. Identifikation Ut Amtsgericht Stuttgart HRB 734603 EUID DEB2609.HRB734603 Adresse Tübingen, Deutschland Gegenstand Entwicklung, die …See details»
SYNIMMUNE GmbH, Tübingen - Biotechnologieunternehmen
Aug 7, 2023 SYNIMMUNE GmbH mit der Handelsregisternummer HRB 734603 (Amtsgericht Stuttgart) ist seit dem 11.08.2010 aktiv. Das Unternehmen ist in der Branchen Forschung & …See details»
SYNIMMUNE (SYNIMMUNE GmbH) - startbase.com
Official Website: synimmune.de; On Social Media: Legal Entity: SYNIMMUNE GmbH Location: Baden-Württemberg Overview Company Funding Product Team News Is this your company? …See details»
Synimmune - Products, Competitors, Financials, Employees, …
Synimmune operates as a biotechnology company focusing on the development of anti-tumor antibodies. The company offers the creation of mono- and bispecific antibodies designed to …See details»
SYNIMMUNE GmbH: Drug pipelines, Patents, Clinical trials - Synapse
Jul 16, 2023 Explore SYNIMMUNE GmbH with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 1 news, Disease Domain:Hemic and Lymphatic Diseases, Immune ...See details»
SYNIMMUNE - Overview, News & Similar companies | ZoomInfo.com
Sep 6, 2021 SYNIMMUNE contact info: Phone number: +49 70717708381 Website: www.synimmune.de What does SYNIMMUNE do? SYNIMMUNE GmbH is a biotechnology …See details»
VERAXA Biotech acquires Synimmune GmbH - Crunchbase
Dec 29, 2023 Acquired Organization: Synimmune GmbH Synimmune GmbH is a biotechnology company. Acquiring Organization: VERAXA Biotech VERAXA Biotech specializes in ADC …See details»
Synimmune GmbH - VentureRadar
Synimmune Inc. is a biotechnology company aiming to commercialize our company’s own immune-oncology products as well as providing R&D services to partner companies that …See details»
SYNIMMUNE GmbH im Startup-Atlas
Über die Firma SYNIMMUNE GmbH. Entwicklung innovativer Antikörpertherapien zur Behandlung lebensbedrohlicher Krankheiten, insbesondere hämatopoetischer Malignitäten, …See details»
SYNIMMUNE - Company Profile - Tracxn
Nov 5, 2024 SYNIMMUNE - German, early-stage biotech developing mono- and bi-specific antibodies for cancer treatment. Acquired by VERAXA. Founded by Hans-George …See details»
1. SYNOPSIS - uni-tuebingen.de
Synimmune GmbH Alte Landstrasse 42 15, 72072 Tuebingen Phone: +49-7071-7708381 FAX: +49-7071-7708383 Email: [email protected] Clinical Research Organization: Center for …See details»
Synimmune GmbH - Contacts, Employees, Board Members
Synimmune GmbH is a biotechnology company. Start Free Trial . Chrome ExtensionSee details»
SYNIMMUNE Company Profile - Office Locations, Competitors
SYNIMMUNE is a biotechnology company dedicated to the development of mono- and bispecific anti-tumor antibodies for the treatment of patients suffering from life-threatening diseases, with …See details»
VERAXA Biotech AG acquires Synimmune GmbH to expand cancer …
Zurich, 29th of December 2023: VERAXA Biotech AG, a pioneering company in the development of superior antibody-based cancer therapies and a portfolio company of Xlife Sciences AG …See details»
Synimmune GmbH sold to Veraxa Biotech AG - lenzstaehelin.com
Dec 29, 2023 Synimmune GmbH, a German biotech company dedicated to the development of innovative anti-tumor antibodies was sold to Veraxa Biotech AG, a portfolio company of SIX …See details»
293C3-SDIE - Drug Targets, Indications, Patents - Synapse - Patsnap
293C3-SDIE: a CD133 inhibitors Drug, Initially developed by SYNIMMUNE GmbH, Now, its global highest R&D status is Pending, Mechanism: CD133 inhibitors(CD133 inhibitors), Therapeutic …See details»